SNPX

Synaptogenix
SNPX
Market cap $3.25M

2.40 USD

-0.21

8.05%

At close Nov 15, 4:00 PM EST

1 day

-8.05%

5 days

-17.81%

1 month

-20.00%

3 months

-35.48%

6 months

-49.04%

Year to date

-67.44%

1 year

-58.26%

5 years

-98.60%

10 years

-98.60%

About: Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Employees: 5

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.14% less ownership

Funds ownership: 0.33% [Q2] → 0.19% (-0.14%) [Q3]

13% less funds holding

Funds holding: 8 [Q2] → 7 (-1) [Q3]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

54% less capital invested

Capital invested by funds: $16.5K [Q2] → $7.61K (-$8.91K) [Q3]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for SNPX.

See Analyst Rankings

Financial journalist opinion

Synaptogenix Announces $5.0 Million Financing

NEW YORK , Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common stock in a registered public offering (the "Registered Offering") and a concurrent private placement (the "Private Placement" and collectively with the Registered Offering, the "Offering") of additional shares of Preferred Stock and unregistered common stock purchase warrants.

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in the treatment of neurodegenerative diseases NEW YORK , July 18, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence for pre-clinical testing of the Company's polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal cord injury (SCI). The Company also announced that the US Patent and Trademark Office (USPTO) recently issued US Patent No.

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , June 26, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that the Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) application for Bryostatin-1 as a potential treatment for multiple sclerosis (MS). The fully-funded, open-label clinical trial will be held and managed at Cleveland Clinic Neurological Institute's Mellen Center for Multiple Sclerosis.

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways NEW YORK , May 7, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today applauds the reported move by the U.S. Drug Enforcement Agency (the "DEA") to recommend reclassifying cannabis as a Schedule III drug, and announces potential benefits of the rescheduling to its partner Cannasoul Analytics ("Cannasoul"), founded by the Technion-Israel Institute of Technology, in its discovery of cannabis-based therapeutics. As reported in the press on April 30, 2024, the DEA will move to reclassify cannabis from a Schedule I drug to a Schedule III under the Controlled Substance Act on recommendation by the U.S. Department of Health and Human Services.

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

NEW YORK , April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for continued listing on The Nasdaq Capital Market. On April 24, 2023, Synaptogenix received notice from the Listing Qualifications Department of Nasdaq indicating that the Company was not in compliance with the Listing Rule, as its common stock had failed to meet a closing bid price of $1.00 or more for 30 consecutive business days.

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Common stock will begin trading on split-adjusted basis on April 5, 2024 NEW YORK , April 3, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares. The reverse stock split will become effective at 5:00 p.m.

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix President Daniel L. Alkon, M.D.

Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK , Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel L. Alkon, M.D.

Synaptogenix President Daniel L. Alkon, M.D.

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Presenters, including Nobel Laureate in Medicine, to discuss innovative treatments for neurodegeneration Company to feature lead therapeutic's statistically significant benefits, p < 0.007, for severe Alzheimer's disease (AD) patients NEW YORK , Dec. 6, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel Alkon, M.D., will join more than 30 leading neuroscientists and academics as a speaker at IABS Forum-2023, "New Concepts for the Treatment of Neurodegenerative Disorders.

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

See News Rankings

Charts implemented using Lightweight Charts™